Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Bayesian inference on stochastic gene transcription from flow cytometry data.

Tiberi S, Walsh M, Cavallaro M, Hebenstreit D, Finkenstädt B.

Bioinformatics. 2018 Sep 1;34(17):i647-i655. doi: 10.1093/bioinformatics/bty568.

PMID:
30423089
2.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
3.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2018 Aug 7. pii: S0163-4453(18)30246-9. doi: 10.1016/j.jinf.2018.08.003. [Epub ahead of print]

PMID:
30096332
4.

Non-tuberculous mycobacterial pulmonary disease: a clinical update.

Rokadiya S, Millar FR, Tiberi S.

Br J Hosp Med (Lond). 2018 Aug 2;79(8):C118-C122. doi: 10.12968/hmed.2018.79.8.C118. No abstract available.

PMID:
30070955
5.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
6.

Tuberculosis elimination: where are we now?

Matteelli A, Rendon A, Tiberi S, Al-Abri S, Voniatis C, Carvalho ACC, Centis R, D'Ambrosio L, Visca D, Spanevello A, Battista Migliori G.

Eur Respir Rev. 2018 Jun 13;27(148). pii: 180035. doi: 10.1183/16000617.0035-2018. Print 2018 Jun 30. Review.

7.

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Guglielmetti L, Tiberi S, Burman M, Kunst H, Wejse C, Togonidze T, Bothamley G, Lange C; TBnet; of the TBnet QTc survey.

Eur Respir J. 2018 Aug 16;52(2). pii: 1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug. No abstract available.

PMID:
29880656
8.

Direct Whole-Genome Sequencing of Sputum Accurately Identifies Drug-Resistant Mycobacterium tuberculosis Faster than MGIT Culture Sequencing.

Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, Bryant JM, Chan J, Creer D, Holdstock J, Kunst H, Lozewicz S, Platt G, Romero EY, Speight G, Tiberi S, Abubakar I, Lipman M, McHugh TD, Breuer J.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00666-18. doi: 10.1128/JCM.00666-18. Print 2018 Aug.

9.

Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases.

Scriven JE, Scobie A, Verlander NQ, Houston A, Collyns T, Cajic V, Kon OM, Mitchell T, Rahama O, Robinson A, Withama S, Wilson P, Maxwell D, Agranoff D, Davies E, Llewelyn M, Soo SS, Sahota A, Cooper MA, Hunter M, Tomlins J, Tiberi S, Kendall S, Dedicoat M, Alexander E, Fenech T, Zambon M, Lamagni T, Smith EG, Chand M.

Clin Microbiol Infect. 2018 Nov;24(11):1164-1170. doi: 10.1016/j.cmi.2018.04.027. Epub 2018 May 25.

PMID:
29803845
10.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Portuguese, English.

11.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
12.

A cluster of two human cases of tick-borne encephalitis (TBE) transmitted by unpasteurised goat milk and cheese in Germany, May 2016.

Brockmann SO, Oehme R, Buckenmaier T, Beer M, Jeffery-Smith A, Spannenkrebs M, Haag-Milz S, Wagner-Wiening C, Schlegel C, Fritz J, Zange S, Bestehorn M, Lindau A, Hoffmann D, Tiberi S, Mackenstedt U, Dobler G.

Euro Surveill. 2018 Apr;23(15). doi: 10.2807/1560-7917.ES.2018.23.15.17-00336.

13.

Defining the best regimen to treat isoniazid-resistant tuberculosis.

Migliori GB, Tiberi S, Sotgiu G.

Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. No abstract available.

PMID:
29595499
14.

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, Caws M, Tiberi S, Bolhuis M, Alffenaar JC, Davies G, Sloan DJ.

J Antimicrob Chemother. 2018 Mar 23. doi: 10.1093/jac/dky096. [Epub ahead of print]

15.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
16.

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!

Tiberi S, Cabibbe AM, Tomlins J, Cirillo DM, Migliori GB.

EBioMedicine. 2018 Mar;29:11-12. doi: 10.1016/j.ebiom.2018.02.006. Epub 2018 Feb 8. No abstract available.

17.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

18.

The critically ill patient with tuberculosis in intensive care: Clinical presentations, management and infection control.

Otu A, Hashmi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, Zumla A, Dünser MW, Mer M.

J Crit Care. 2018 Jun;45:184-196. doi: 10.1016/j.jcrc.2018.03.015. Epub 2018 Mar 13. Review.

PMID:
29571116
19.

Accelerating the development of therapeutic strategies for drug-resistant tuberculosis.

Vjecha MJ, Tiberi S, Zumla A.

Nat Rev Drug Discov. 2018 Sep;17(9):607-608. doi: 10.1038/nrd.2018.28. Epub 2018 Mar 23.

PMID:
29567994
20.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

PMID:
29567720
21.

Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients.

Veronese G, Ammirati E, Moioli MC, Baldan R, Orcese CA, De Rezende G, Veronese S, Masciocco G, Perna E, Travi G, Puoti M, Cipriani M, Tiberi S, Cirillo D, Frigerio M.

Transpl Infect Dis. 2018 Jun;20(3):e12880. doi: 10.1111/tid.12880. Epub 2018 Mar 25.

PMID:
29514393
22.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
23.

Shigellosis and toxic megacolon secondary to Shigella flexneri serotype 3a: The challenges of laboratory diagnosis.

McGuire E, Tiberi S, Ciesielczuk H, Melzer M.

Int J Infect Dis. 2018 May;70:104-106. doi: 10.1016/j.ijid.2018.02.020. Epub 2018 Mar 2.

24.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24.

25.

Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.

Tadolini M, Tiberi S, Migliori GB.

Lancet Infect Dis. 2018 May;18(5):480-481. doi: 10.1016/S1473-3099(18)30106-3. Epub 2018 Feb 13. No abstract available.

PMID:
29452940
26.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8.

27.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

PMID:
29146605
28.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

29.

Post-implementation blues: the unfulfilled potential of Xpert.

Tiberi S, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1073. doi: 10.5588/ijtld.17.0478. No abstract available.

PMID:
28911347
30.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

31.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

32.

Intestinal tuberculosis: a diagnostic challenge.

Kentley J, Ooi JL, Potter J, Tiberi S, O'Shaughnessy T, Langmead L, Chin Aleong J, Thaha MA, Kunst H.

Trop Med Int Health. 2017 Aug;22(8):994-999. doi: 10.1111/tmi.12908. Epub 2017 Jul 5.

33.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

PMID:
28596434
34.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

35.

A composite likelihood approach to predict the sex of the baby.

Tiberi S, Scarpa B, Sartori N.

Stat Methods Med Res. 2018 Nov;27(11):3386-3396. doi: 10.1177/0962280217702415. Epub 2017 Apr 10.

PMID:
28395600
36.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
37.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

38.

Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.

Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; for TBNET ‡.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1222-1224. doi: 10.1164/rccm.201612-2585LE. No abstract available.

PMID:
28323453
39.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
40.

The cursed duet today: Tuberculosis and HIV-coinfection.

Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, Rahman A, Matin N, Zumla A, Pontali E.

Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. doi: 10.1016/j.lpm.2017.01.017. Epub 2017 Feb 28. Review.

PMID:
28256380
41.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

42.

Imaging features and diagnosis of tuberculosis of the breast.

Longman CF, Campion T, Butler B, Suaris TD, Khanam A, Kunst H, Tiberi S, O'Keeffe SA.

Clin Radiol. 2017 Mar;72(3):217-222. doi: 10.1016/j.crad.2016.11.023. Epub 2017 Jan 6.

PMID:
28065639
43.

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Rendon A, Tiberi S, Scardigli A, D'Ambrosio L, Centis R, Caminero JA, Migliori GB.

J Thorac Dis. 2016 Oct;8(10):2666-2671. No abstract available.

44.

WHO recommendations for multidrug-resistant tuberculosis - Authors' reply.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Zumla A, Migliori GB.

Lancet. 2016 Nov 5;388(10057):2234-2235. doi: 10.1016/S0140-6736(16)31465-9. No abstract available.

PMID:
27825499
45.

Classifying new anti-tuberculosis drugs: rationale and future perspectives.

Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Caminero Luna JA.

Int J Infect Dis. 2017 Mar;56:181-184. doi: 10.1016/j.ijid.2016.10.026. Epub 2016 Nov 3.

46.

Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.

Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, Migliori GB.

Int J Infect Dis. 2017 Mar;56:190-193. doi: 10.1016/j.ijid.2016.10.021. Epub 2016 Nov 2.

47.

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D'Ambrosio L, Sadutshang TD, Centis R, Migliori GB.

Eur Respir J. 2016 Nov;48(5):1527-1529. doi: 10.1183/13993003.01552-2016. No abstract available.

48.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

49.

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP.

Clin Infect Dis. 2017 Jan 1;64(1):104-105. Epub 2016 Oct 6. No abstract available.

PMID:
27789609
50.

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.

Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.

Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. Epub 2016 Oct 24. Review.

PMID:
27762157

Supplemental Content

Loading ...
Support Center